Clinical effectiveness of pharmacist administration of long‐acting injectable buprenorphine: Findings from the EPIC‐MATOD study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Subject Terms:
    • Abstract:
      The article discusses the clinical effectiveness of pharmacist-administered long-acting injectable buprenorphine (LAIB) as a form of opioid agonist treatment (OAT) in Victoria, Australia. The EPIC-MATOD study explores a collaborative care model involving pharmacists and prescribers to provide LAIB treatment, resulting in high patient and healthcare provider satisfaction. The study highlights the benefits of pharmacist-administered LAIB, such as simplified care, reduced travel burdens, and increased treatment access, potentially addressing OAT prescriber shortages in Australia and beyond. [Extracted from the article]
    • Abstract:
      Copyright of Drug & Alcohol Review is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)